Literature DB >> 27200875

Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis With Certolizumab Pegol: 96-Week Patient-Reported Outcome Results Of The Rapid-Psa Study.

D Gladman1, R Fleischmann2, B Szegvari3, L Peterson4, P J Mease5.   

Abstract

Entities:  

Year:  2014        PMID： 27200875     DOI： 10.1016/j.jval.2014.08.2646

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  2 in total

Review 1.  Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

2.  Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.

Authors:  Annunziata Dattola; Maria Vittoria Cannizzaro; Mauro Mazzeo; Luca Bianchi
Journal:  Dermatol Ther (Heidelb)       Date:  2017-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.